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Thesis Synopsis 
Introduction 
Glioma, the tumor of glial cells, is one of the common types of primary central 
nervous system (CNS) neoplasms.  Astrocytoma is the most common of all gliomas and 
originates from astrocytic glial cells.  Astrocytoma tumors belong to two main categories: 
benign tumors, comprising of grade I Pilocytic astrocytoma and malignant tumors which 
diffusely infiltrate throughout the brain parenchyma.  Diffusely infiltrating astrocytomas are 
graded into diffuse astrocytoma (DA; grade II), anaplastic astrocytoma (AA; grade III) and 
glioblastoma (GBM; grade IV) in the order of increasing malignancy.  Patients with grade II 
astrocytoma have a median survival time of 6 to 8 years after surgical intervention.  While 
the more aggressive grade III (AA) and grade IV (GBM) are together called malignant 
astrocytomas, the treatment protocols and length of survival are distinctly different between 
these grades.  The median survival time for grade III patients is 2 to 3 years whereas patients 
with grade IV have a median survival of 12-15 months.  GBMs have been further divided 
into primary GBM and secondary GBM on the basis of clinical and histopathological criteria.  
Primary GBM presents in an acute de novo manner with no evidence of an antecedent lower 
grade tumor and it accounts for >90% of all GBMs.  In contrast, secondary GBM results 
from the progressive malignant transformation of a grade II or grade III astrocytoma.   
The current WHO grading system of astrocytomas is based on the histopathological 
characteristics of the underlying tumor tissue.  Diagnoses by pathologists are dependent on 
specific histologic features: increased mitosis, nuclear atypia, microvascular proliferation 
and/or necrosis, which associate with biologically aggressive behaviour (WHO 2007).  
Though grading based on histology is largely reproducible and well accepted, subjectivity 
involved and substantial disagreement between pathologists has remained a major concern.  
Because of inherent sampling problems (mainly due to tumor location in the brain) and 
inadequate sample size available for histological evaluation, there exists a very high 
possibility of error in grading.   
Recent studies have attempted to characterize the molecular basis for the histological 
and prognostic differences between grade III and grade IV astrocytoma.  While reports have 
shown the grade specific profile of gene expression, there is no molecular signature that can 
accurately classify grade III and grade IV astrocytoma samples.  In the current work, we have 
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identified molecular signatures for the accurate classification of grade III and grade IV 
astrocytoma patients by using transcriptome and miRNome data.   
The receptor tyrosine kinase pathway is known to be overexpressed in 88% of 
glioblastoma patients.  The expression and activation of the receptors is reported to be 
deregulated by events like amplification and activating mutations.  The aberrant expression 
of RTKs could also be due to the deregulation of miRNAs, which, in the untransformed 
astrocytes regulate and fine-tune the levels of the RTKs.  In the current study, we have 
identified that tumor suppressor miRNA miR-219-5p regulates RTK pathway by targeting 
EGFR and PDGFRα.   
Part I. Transcriptome approach: Identification of a 16-gene signature for classification 
of malignant astrocytomas 
In order to obtain a more robust molecular classifier to accurately classify grade III 
and grade IV astrocytoma samples, we used transcriptome data from microarray study 
previously performed in our laboratory.  The differential regulation of 175 genes identified 
from microarray was validated in a cohort of grade III and grade IV patients by real-time 
qRT-PCR.  In order to identify the classification signature that can classify grade III and 
grade IV astrocytoma samples, we used the expression data of 175 genes for performing 
Prediction Analysis of Microarrays (PAM) in the training set of grade III and grade IV 
astrocytoma samples.  PAM analysis identified the most discriminatory 16-gene expression 
signature for the classification of grade III and grade IV astrocytoma.  The Principal 
Component Analysis (PCA) of 16-genes astrocytoma patient samples revealed that the 
expression of 16-genes could classify grade III and grade IV astrocytoma samples into two 
separate clusters.  In the training set, the 16-gene signature was able to classify grade III and 
grade IV patients with an accuracy rate of 87.9% as tested by additional analysis of Cross-
Validated probability by PAM.  The 16-gene signature obtained in the training set was 
validated in the test set with diagnostic accuracy of 89%.  We further validated the 16-gene 
signature in three independent cohorts of patient samples from publicly available databases: 
GSE1993, GSE4422 and TCGA datasets and the classification signature got validated with 
accuracy rates of 88%, 92% and 99% respectively.  To address the discordance in grading 
between 16-gene signature and histopathology, we looked at the clinical features (age and 
survival) and molecular markers (CDKN2A loss, EGFR amplification and p53 mutation) that 
differ substantially between grade III and grade IV in discordant grade III and grade IV 
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samples.  The grading done by 16-gene signature correlated with known clinical and 
molecular markers that distinguish grade III and grade IV proving the utility of the 16-gene 
signature in the molecular classification of grade III and grade IV.  In order to identify the 
pathways that 16 genes of the classification signature could regulate, we performed protein-
protein interaction network and subsequently pathway analysis.  The pathways with highest 
significance were ECM (extracellular matrix) and focal adhesion pathways, which are known 
to be involved in the epithelial to mesenchymal transition (EMT), correlating well with the 
aggressive infiltration of grade IV tumors. In addition to accurately classifying the grade III 
and grade IV samples, the 16-gene signature also demonstrated that genes involved in 
epithelial-mesenchymal transition play key role in distinguishing grade III and grade IV 
astrocytoma samples.   
Part II. miRNome approach 
microRNAs (miRNAs) have emerged as one of the important regulators of the 
interaction network that controls various cellular processes.  miRNAs are short non-coding 
RNAs (mature RNA being 21-22nt long) that regulate the target mRNA by binding mostly in 
the 3’ UTR bringing about either translational repression or degradation of the target.  
miRNAs are shown to play key roles in cell survival, proliferation, apoptosis, migration, 
invasion and various other characteristic features that get altered in human cancers.  miRNAs 
are characterized to have oncogenic or tumor suppressor role and the aberrant expression of 
miRNAs is reported in multiple human cancer types.   
Part A. Genome-wide expression profiling identifies deregulated miRNAs in malignant 
astrocytoma 
With an aim to identify the role of miRNAs in the development of in malignant 
astrocytoma, we performed a large-scale, genome-wide microRNA (miRNA) (n=756) 
expression profiling of 26 grade IV astrocytoma, 13 grade III astrocytoma and 7 normal brain 
samples.  Using Significance Analysis of Microarrays (SAM), we identified several 
differentially regulated miRNAs between control normal brain and malignant astrocytoma, 
grade III and grade IV astrocytoma, grade III astrocytoma and grade IV secondary GBM, 
progressive pathway and de novo pathway of GBM development and also between primary 
and secondary GBM.  Importantly, we identified a most discriminatory 23-miRNA 
expression signature, by using PAM, which precisely distinguished grade III from grade IV 
astrocytoma samples with an accuracy of 90%.  We re-evaluated the grading of discordant 
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samples by histopathology and identified that one of the discordant grade III samples had 
areas of necrosis and it was reclassified as grade IV GBM.  Similarly, out of two discordant 
grade IV samples, one sample had oligo component and it was reclassified as grade III mixed 
oligoastrocytoma.  Thus, after the revised grading, the prediction accuracy increased from 
90% to 95%.  The differential expression pattern of nine miRNAs was further validated by 
real-time RT-PCR in an independent set of malignant astrocytomas (n=72) and normal 
samples (n=7).  Inhibition of two glioblastoma-upregulatedmiRNAs (miR-21 and miR-23a) 
and exogenous overexpression of two glioblastoma-downregulatedmiRNAs (miR-218 and 
miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on 
cell proliferation and chemosensitivity.  Thus, we have identified the grade specific 
expression of miRNAs in malignant astrocytoma and identified a miRNA expression 
signature to classify grade III astrocytoma from grade IV glioblastoma.  In addition, we have 
demonstrated the functional relevance of miRNA modulation and thus showed the miRNA 
involvement and their importance in astrocytoma development.   
Part B. miR-219-5p inhibits the receptor tyrosine kinase pathway by targeting 
mitogenic receptor kinases in glioblastoma 
The receptor tyrosine kinase (RTK) pathway, being one of the important growth 
promoting pathways, is known to be deregulated in 88% of the patients with glioblastoma.  
In order to understand the role of miRNAs in regulating the RTK pathway, we undertook a 
screening procedure to identify the potential miRNAs that could target different members of 
the RTK pathway. From the screening study involving bioinformatical prediction of miRNAs 
and subsequent experimental validation by modulation of miRNA levels in glioma cell lines, 
we identified miR-219-5p as a candidate miRNA.  The overexpression of miR-219-5p 
reduced the protein levels of both EGFR and PDGFRα.  We confirmed the binding of miR-
219-5p to the 3’ UTRs by using reporter plasmids.  We also confirmed the specificity of 
miR-219-5p binding sites in the 3’ UTR of EGFR by site directed mutagenesis of binding 
sites which abrogated the miRNA-UTR interaction.  The expression of miR-219-5p was 
significantly downregulated in grade III as well as in grade IV astrocytoma samples in the 
miRNA microarray experiment and we further validated the downregulation in an 
independent cohort of grade III and grade IV astrocytoma patients by real-time qRT-PCR.  
The ectopic overexpression of miR-219-5p in glioma cell lines inhibited cell proliferation, 
colony formation, anchorage independent growth and the migration of glioma cells.  In 
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addition, overexpression of miR-219-5p decreased MAPK and PI3K pathways, in 
concordance with its ability to target EGFR and PDGFRα.  Additionally, for the further 
characterization of miR-219-5p – EGFR interaction and its effect on MAPK and PI3K 
pathways, we used U87 glioma cells that stably overexpress wild-type EGFR and 
constitutively active ΔEGFR (both lacking 3’-UTR and thus being insensitive to miR-219-5p 
overexpression) along with U87 parental cells.  In these cell lines with the overexpression of 
EGFR lacking 3’-UTR, miR-219-5p was unable to inhibit - MAPK and PI3K pathways and 
also glioma cell migration suggesting that these effects were indeed because of its ability to 
target EGFR.  Further, in the glioblastoma patient cohort (TCGA dataset), we found 
significant negative correlation between EGFR protein levels, both total EGFR and phospho 
EGFR and miR-219-5p levels in the glioblastoma tissue samples suggesting a role of miR-
219-5p in increasing the protein levels of EGFR in glioblastoma.  In summary, we have 
identified and characterized miR-219-5p as the RTK regulating tumor suppressor miRNA in 
glioblastoma.    
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